Supplementary Figure 4 from T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 152K, Comparison of CAR.CSPG4+ and CAR.CD19+ T lymphocytes. Panel A. Expression of CAR.CD19 and CAR.CSPG4 in T lymphocytes after retroviral transduction, as assessed by FACS. Panel B. Co-culture experiments in which CAR.CSPG4+ T cells, CAR.CD19+ T cells, and control (non-transduced) cells were cultured with GFP+ tumor cell lines. Pictures illustrate the elimination of CSPG4+eGFP+ target (SENMA) by CAR.CSPG4+ T cells and not by CAR.CD19+ T cells or control T cells after 72 hours of co-culture. The CSPG4- cell lines P1143 was not targeted by either CAR.CSPG4+ T cells or CAR.CD19+ T cells. Panel C. Proliferation of control (non-transduced), CAR.CD19+, and CAR.CSPG4+ T cells upon stimulation with CSPG4+ target in a 96 hour CFSE dilution assay. Data are representative of three independent experiments using irradiated SENMA tumor cells. Panel D. Control (non transduced), CAR.CD19+, and CAR.CSPG4+ T cells were evaluated in a 6 hour cytotoxicity assay against SENMA (CSPG4+), K562 (natural killer cell target), and P1143 (CSPG4-). Data represents the average of three experiments with mean � SD.
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361908231